NASDAQ:ITUS

ITUS (ITUS) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$4.61
$4.76
50-Day Range
N/A
52-Week Range
$1.83
$6.43
Volume
69,859 shs
Average Volume
134,373 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ITUS stock logo

About ITUS Stock (NASDAQ:ITUS)

Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body's immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immune-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

ITUS Stock News Headlines

Clear skies for your Sunday
One trade. One ticker. One week.
Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week?
One trade. One ticker. One week.
Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week?
Sunny skies for your Sunday
Seasonably cool Thursday with sunshine
Scattered showers for your Wednesday
Chilly weather for the holidays
See More Headlines
Receive ITUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ITUS and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/09/2018
Today
4/23/2024

Industry, Sector and Symbol

Industry
Patent Owners & Lessors
Sub-Industry
N/A
Current Symbol
NASDAQ:ITUS
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Amit D. Kumar
    Executive Chairman, President & CEO
  • Michael J. Catelani
    Secretary, Chief Operating & Financial Officer
  • Thomas Schlumpberger
    Executive Vice President-Diagnostics

ITUS Stock Analysis - Frequently Asked Questions

How were ITUS's earnings last quarter?

ITUS Co. (NASDAQ:ITUS) announced its earnings results on Friday, March, 9th. The business services provider reported ($0.11) earnings per share for the quarter.

What other stocks do shareholders of ITUS own?
This page (NASDAQ:ITUS) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners